Observation vs Progesterone Treatment for Management of Uterine Arteriovenous Malformation

HaEmek Medical Center, Israel28 enrolled

Overview

A randomized trial which compares conservative management to progesterone based treatment for arteriovenous malformation

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Arteriovenous Malformations

Interventions

MedroxyPROGESTERone Injection [Depo-Provera]DRUG

The drug-induced endometrial changes would likely to prevent the shedding of endometrium, in turn preventing the exposure of AVM.

OtherDEVICE

Follow up using US

Eligibility

Sex: FEMALEMin age: 18 YearsMax age: 50 Years

Medical Language ↔ Plain English

Inclusion Criteria: * women between age of 18 to 50, diagnosed with AVM * hemodynamically stable at clinical presentation Exclusion Criteria: * unstable patients * contraindication to treatment * US examination not in the US department

Outcomes

Primary Outcomes

AVM regression

The time from diagnosis to regression

Time frame: 3 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.